{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'population for the description of the patient and treatment characteristics and is used for the', 'primary efficacy analysis.', 'Per-protocol (PP) population:', 'This population will include all randomized patients fulfilling the inclusion and exclusion criteria', 'and who received at least one cycle of active treatment with at least one documented', 'structured follow-up visits (Arm A) or with at least one documented follow-up visit (Arm B).', 'Treatment assignment is based on the treatment actually received.', 'Safety analysis set:', 'The safety population for chemotherapy related toxicities comprises all patients who received', 'at least one administration of mFOLFOXIRI/mFOLFOX-6 after randomization.', 'Several subgroup analyses including but not limited to prior systemic therapy (with VS. without', 'prior systemic therapy), resection status (R1 VS. R0 resected lesions) and type of definite', 'treatment of colorectal cancer metastases (ablated vs. purely resected lesions) are planned.', 'In addition, and more explorative, subgroups might be defined based on circulating tumor DNA', 'status at baseline (ctDNA positive VS. negative) and other molecular parameters. Further', 'details will be specified in the SAP.', '8.3 Further Analysis', 'In addition, multiple types of machine learning (ML) models will be retrospectively applied on', 'the data to evaluate the potential of ML-algorithms in predicting the occurrence of the primary', 'as well as secondary endpoints on an exploratory basis. The ML models will use all categorical', 'and numerical data outlined above and supervised and unsupervised learning models shall be', 'tested. For analysis, model selection and hyperparameter optimization, the baseline dataset', 'will be split into training and evaluation data using stratified k-fold crossvalidation. For', 'supervised binary classification (e.g. PFS within 24 months) Logistic Regression, Support', 'Vector Classifier and Neural Networks will be performed. Unsupervised learning algorithms', 'will entail K-Nearest Neighbor or a Gaussian Mixture Model after principal component analysis.', 'The evaluation of ML-algorithms with respect to their test performance criteria will be', 'conducted using receiver operating characteristic (ROC) curves, which indicate the', 'discriminatory power of a diagnostic test. The ROC curve describes the dependence of', 'sensitivity (true positive rate) and 1-specificity (false positive rate) for different threshold values', 'of the ML classifier. The Area Under the Curve (AUC) of the ROC will subsequently be applied', 'to quantify the classification performance of each model at all classification thresholds.', 'Depending on the balance of the dataset, precision-recall AUC will additionally be used for', 'classifier performance testing.', 'Data cleaning and preprocessing will be conducted with Python using the Anaconda/Jupyter-', 'Notebook (Anaconda Inc., Austin, TX, USA). ML algorithm calculation and testing will be', 'performed with SKLearn [Buitinck et al., 2013]. Modelling of Neuronal Networks in particular', 'will furthermore require Tensor Flow [Abadi et al., 2016].', 'Confidential', 'Page 62 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '9', 'Study Medication', 'This section provides an overview on the study medication used. It is not intended to replace', 'the careful reading of the summary of product characteristics (SmPC) for each component,', 'which contains details on drug characteristics, storage, application, mode of action and', 'adverse reactions. All substances within the FOLFOX / FOLFOXIRI regimen are market', 'approved in Germany/Europe for at least one kind of tumor. Moreover, the regimens are', 'standard of care for patients with of lower stages of colorectal cancer. Therefore, the protocol', 'requires limited documentation of concomitant medication with regard to FOLFOX /', 'FOLFOXIRI in this trial. If patients receive concomitant medication, the product characteristics', 'need to be checked by the investigator with respect to potential drug interactions. In case of', 'any doubt, the lead coordinating investigator shall be consulted. The investigator or the', 'pharmaceutical expert in delegation is responsible for the safe storage, preparation, release,', 'and documentation of the study medication with respect to standard procedures and national', 'guidelines. All medication shall be distributed according to the prescription of the investigator', '9.1 mFOLFOX-6', '9.1.1', 'Oxaliplatin', 'Oxaliplatin (trade name: e.g. Eloxatin\u00ae) is presented as a clear, colourless concentrate in glass', 'vials of 20 mL containing 100 mg active compound and to be diluted for preparation of an', 'infusion solution. Oxaliplatin will be administered in 500mL of 5% glucose solution as a two-', 'hour i.v. infusion. Oxaliplatin should always be administered before 5-FU. For further', 'information see the respective SmPC (Summary of Product Characteristics, Fachinformation).', 'Oxaliplatin is a cytotoxic anticancer drug and, as with other potentially toxic compounds,', 'caution should be exercised when handling and preparing oxaliplatin solutions. The use of', 'gloves is recommended.', 'If oxaliplatin concentrate, initial diluted solution, or infusion solution should come into contact', 'with skin, immediately and thoroughly wash with soap and water. If oxaliplatin concentrate,', 'initial diluted solution, or infusion solution should come into contact with mucosa, immediately', 'and thoroughly wash with water.', 'Do not combine with alkaline medications or media that cause oxaliplatin to degrade. Do not', 'administer other agents simultaneously by the same line. Flush line after oxaliplatin', 'administration before using the line to administer other agents. Do not use preparation /', 'administration needles or intravenous administration sets containing aluminium parts, as', 'aluminium has been reported to cause degradation of platinum compounds.', '9.1.1.1 Possible Adverse Effects of Oxaliplatin', 'Nausea/vomiting, diarrhea, leukopenia, thrombocytopenia, anemia, increase of liver enzymes,', 'alopecia, peripheral neurotoxicity. Please refer to the respective SmPC for further details.', 'Confidential', 'Page 63 of 79']\n\n###\n\n", "completion": "END"}